Article

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?

2023-09-11

Abstract excerpt

De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5-10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. This review describes the current therapeutic opportuniti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d0e85276-6c12-56d7-a761-ae3dd155fe92
DOI: 10.20944/preprints202309.0633.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?DOI 10.20944/preprints202309.0633.v1Read

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Semantic proximity Read

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancerSemantic proximity Read

Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype.Semantic proximity Read

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancerSemantic proximity Read

Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy.Semantic proximity Read

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerSemantic proximity Read

The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and TherapySemantic proximity Read

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.Semantic proximity Read

Translational and clinical implications of the genetic landscape of prostate cancer.Semantic proximity Read

Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic FrontiersSemantic proximity Read

Molecular Subtypes of Prostate Cancer.Semantic proximity Read

Prostate cancer heterogeneity: Discovering novel molecular targets for therapySemantic proximity Read